Arkolith/Insider Trading/MAZE/Form 4

Bernstein Harold

President, R&D & CMOMaze Therapeutics, Inc. (MAZE) · full profile →Form 4 · filed Apr 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$442K
Net Open-Market Flow
-$442K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)15K$10.42$156K15K
Apr 1, 2026Sell(S)11K$29.24$332K4K
Apr 1, 2026Sell(S)3K$30.06$101K300
Apr 1, 2026Sell(S)300$31.07$9K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)15K—$0237K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002050172-26-000019) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML